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Abstract
Background: Non–small cell lung cancer is associated with high expression of multidrug resistance (MDR) proteins
and low production of reactive oxygen species (ROS). Coptis extract (COP), a Chinese medicinal herb, and its major
constituent, berberine (BER), have anticancer properties. This study aims to investigate the effects of COP and BER
combined with chemotherapeutic agents, including fluorouracil (5-FU), camptothecin (CPT), and paclitaxel (TAX), on
cell proliferation, ROS production, and MDR in A549 human non-small cell lung cancer cells.
Methods: A549 cells were treated with different doses of COP and BER, combined with 5-FU, CPT, and TAX. Cell
viability was measured by an XTT (2,3-bis-(2-methoxy-4- nitro-5-sulfophenyl)-2 H-tetrazolium-5-carboxanilide) assay.
Intracellular ROS levels were determined by measuring the oxidative conversion of cell permeable 2′,7′-
dichlorofluorescein diacetate to fluorescent dichlorofluorescein. MDR of A549 cells was assessed by rhodamine 123
retention assay.
Results: Both COP and BER significantly inhibited A549 cell growth in a dose-dependent manner. Combinations of
COP or BER with chemotherapeutic agents (5-FU, CPT, and TAX) exhibited a stronger inhibitory effect on A549 cell
growth. In addition, COP and BER increased ROS production and reduced MDR in A549 cells.
Conclusion: As potential adjuvants to chemotherapy for non–small cell lung cancer, COP and BER increase ROS
production, reduce MDR, and enhance the inhibitory effects of chemotherapeutic agents on A549 cell growth.
Background
The herb Coptis (COP) is used to treat “damp heat” syn-
drome in Chinese medicine [1]. Its major constituent is
berberine (BER), an isoquinoline alkaloid [2]. The antican-
cer effects of COP and BER on both hematological
and nonhematological cancers have been well docu-
mented [3]. Since 2000, experimental studies have
confirmed the cytotoxicity of BER in various cancer
cell lines, including YES (esophageal carcinoma) [4],
HK1 (nasopharyngeal carcinoma) [5], HeLa (cervical
carcinoma) [6], HepG2 (hepatocellular carcinoma)
[7]. Our previous studies [9,10] have also shown that
COP inhibits the growth of breast cancer cells.
Non–small cell lung cancer (NSCLC) accounts for
approximately 85% of lung cancers, and only responds
to 15%–25% single agents and 25%–40% combined
chemotherapy [11]. NSCLC is typically resistant to
apoptosis induced by standard chemotherapy, which
causes excessive levels of reactive oxygen species
(ROS), leading to impaired intracellular ionic homeo-
stasis by damaging cellular macromolecules and indu-
cing apoptosis [12]. Mitochondrial ROS production is
crucial to NSCLC apoptosis induced anticancer agents
[13]. In addition to ROS, multidrug-resistance (MDR)
proteins are intrinsically expressed and functionally active
in NSCLC cells [14]. Several adjuvants to chemotherapy
for NSCLC are being tested, with promising results, in-
cluding the antagonists of EGFR and COX-2 [15-17].
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BER on ROS production and MDR, and the effects of
combinations of COP or BER with chemotherapeutic
agents, including fluorouracil (5-FU), camptothecin (CPT),
and paclitaxel (TAX) on A549 human cancer cells, which
are derived from NSCLC [18].
Methods
Materials
A powder form of COP extract was made from Coptis
japonica (Mayway Corporation, Oakland, CA, USA) by
boiling the plant in water and spray drying. A solution
of COP was prepared as previously described [10]. BER,
5-FU, CPT, and TAX were purchased from Sigma-
Aldrich (USA). BER, 5-FU, and CPT were dissolved in
dimethylsulfoxide (DMSO) (Sigma-Aldrich, USA), and
TAX was dissolved in 100% ethanol (Fisher Scientific,
USA). The final concentrations of DMSO and ethanol
in the medium were less than 0.1%.
Cell culture
The A549 cell line (ATCC CCL-185) was purchased
from ATCC (Manassas, VA, USA). The cells were cul-
tured in Dulbecco's Modified Eagle Medium (DMEM)
(Invitrogen, Carlsbad, CA, USA) supplemented with 100
U/mL penicillin, 100 g/mL streptomycin, and 10% inac-
tivated fetal calf serum (FBS, HyClone, South Logan,
UT, USA). The cells were incubated at 37°C under a hu-
midified atmosphere of 95% air and 5% CO2. Cells were
subcultured twice weekly.
Cell viability assay
A549 cells were seeded in 96-well plastic plates (3 × 10
3
cells/well) and incubated at 37°C in complete medium
for 16 h before the drug treatment for 72 h. Cell viability
was assessed by the XTT (2,3-bis-(2-methoxy-4- nitro-5-
sulfophenyl)-2 H-tetrazolium-5-carboxanilide) assay
(Invitrogen, Carlsbad, CA, USA) . The spectrophotomet-
ric absorbance of the samples was measured using a
microplate reader (VICTOR
3 V
™ 1420 Multilabel Coun-
ter, PerkinElmer, Waltham, MA, USA) at 490 nm with a
reference wavelength of 690 nm. Each measurement was
performed in triplicate and the data reported were mean
values of at least 3 experiments. The inhibitory effect
was calculated according to the following equation:
Inhibition % ðÞ ¼ 1− A490 of treated wells=A490 of control wells ðÞ ½ 
 100:
Measurement of reactive oxygen species
Intracellular ROS levels were determined by measuring
the oxidative conversion of cell permeable 2′,7 ′ dichlor-
ofluorescein diacetate (DCFH-DA; Sigma-Aldrich, USA)
to fluorescent dichlorofluorescein (DCF) [13]. Cells were
plated in 24-well culture plates (2 × 10
5 cells/well) and
incubated with drugs for 24 h. The cells were then
washed with D-Hank’s solution (Invitrogen, USA) and
incubated with 10 μM DCFH-DA in phenol-red-free
MEM medium (Invitrogen, USA) at 37°C for 15 min.
DCF fluorescence distribution was measured in a micro-
plate reader (PerkinElmer, Waltham, MA, USA) at an
excitation wavelength of 488 nm and emission wave-
length of 535 nm. The fluorescence intensity was nor-
malized according to the number of cells.
Rhodamine 123 retention assay
Rhodamine 123 retention was measured to evaluate the
multidrug resistance (MDR) of cancer cells [19,20].
Briefly, 24-well plates with 2 × 10
5 cells/well were trea-
ted with low or high doses of COP (low dose: 1.6 μg/
mL, high dose: 6.4 μg/mL) and BER (low dose: 0.5 μg/
mL, high dose: 4 μg/mL) for 24 h. The cells were then
incubated in phenol-red-free MEM containing 10 μg/mL
rhodamine 123 (Sigma-Aldrich, USA) and 2% FBS for
20 min at 37°C. After incubation, the cell monolayers
were washed 3 times with ice-cold phosphate buffered
saline (PBS), trypsinized, and suspended in MEM
medium containing 2% FBS. The cell suspension was
transferred to a 96-well plate and measured in a micro-
plate reader (PerkinElmer,Waltham, MA, USA) at an ex-
citation wavelength of 485 nm and emission wavelength
of 535 nm. The fluorescence intensity was normalized
by the number of cells. All experiments were performed
in quadruplicate.
Statistical analysis
T h ed a t aw e r ee x p r e s s e da sm e a n s±s t a n d a r dd e v i a -
tions (SD). A one-way ANOVA was performed to test
the difference among groups of controls, individual
agents, and combinations of agents using Graph Pad
Prism 4 software (San Diego, CA, USA). Newman-
Keuls tests were used for multiple comparisons. The
software did not provide exact P values for ANOVA;
thus, no exact P values are reported. The results with
P<0.05 were considered statistically significant. Each
experiment was repeated at least 3 times.
Results
A549 cell growth
The A549 cell line was treated with different doses of
COP and BER and tested for cell viability with an XTT
assay to examine the effects of COP and BER on cancer
cell growth. As shown in Figure 1, treatment with COP
at 6.4 to 51.2 μg/mL or BER at 2.0 to 16.0 μg/mL for
72 h significantly inhibited A549 cell growth. The max-
imum inhibition rates were 60% and 64% for COP and
BER, respectively. A Pearson Correlation Test by Prism
4 was used to determine the correlation between the
He et al. Chinese Medicine 2012, 7:11 Page 2 of 6
http://www.cmjournal.org/content/7/1/11doses of COP or BER and the inhibitory effects on A549
cell growth. The results indicated that the growth inhib-
ition was in a dose-dependent manner [P=0.0032 for
COP; P=0.0178 for BER].
Low and high doses of COP or BER combined with
5FU, CPT, or TAX were used to treat A549 cells to in-
vestigate the inhibitory effects of COP and BER in com-
bination with chemotherapeutic drugs on cancer cells.
As shown in Figure 2, a combination of a low dose of
COP and chemotherapeutic drugs had an inhibitory ef-
fect stronger than CPT or TAX alone on cancer cell
growth (P<0.001 for both CPT and TAX), whereas high
doses of COP enhanced the inhibitory effects of CPT,
TAX, and 5FU on A549 cell growth (P<0.001 for CPT,
TAX, and 5FU). In addition, the combination of a high
dose of BER with chemotherapeutic drugs exhibited an
inhibitory effect stronger than CPT, TAX, or 5FU alone
on A549 cell growth. These findings suggest a potential
use of COP and BER as adjuvant therapies for NSCLC.
Production of reactive oxygen species in A549 cells
The intracellular levels of ROS production were mea-
sured after treatment with low or high doses of COP
and BER. As shown in Figure 3, low doses of COP and
BER increased ROS production by approximately 50%
(P<0.05), relative to the control group, and ROS
production in the cells incubated with high doses of
COP and BER was nearly 3 times that of the control
group (P<0.01, n=4).
Our results show that both COP and BER significantly
increased ROS levels in A549 cells, in a dose-dependent
manner, and enhanced the inhibitory effect of che-
motherapeutic drugs on A549 cells. The present study
agrees with previous findings that ROS production is
increased in cancer cells [21], which sensitizes the can-
cer cells to drugs [13,22] and to radiotherapy [23]. It has
been reported [24] that BER enhances the anticancer ef-
fect of irradiation by increasing ROS production in
human hepatoma cells.
Inhibition of MDR in A549 cells
Rhodamine 123 retention in A549 cells was tested to de-
termine whether COP and BER affect MDR. As shown
in Figure 4, both low and high doses of COP and BER
enhanced dye retention by as much as 40% (P<0.05).
Because elevated dye retention levels are inversely
Figure 1 Effects of COP and BER on the growth of A549 cells. A. Morphological changes of A549 cells treated with 6.4 μg/mL COP or 4.0 μg/
mL BER for 72 h under inverted phase contrast microscope (200 ×). B. Treatment with COP and BER for 72 h inhibited A549 cell growth (P<0.01)
[Pearson Correlation Test, P=0.0032 for COP; P=0.0178 for BER] in a dose-dependent manner. Values are means±SD of 4 independent assays.
He et al. Chinese Medicine 2012, 7:11 Page 3 of 6
http://www.cmjournal.org/content/7/1/11related to MDR [20], this suggests that the inhibitory
effects of COP and BER on A549 cells were enhanced
due to the prolonged intracellular retention of the che-
motherapeutic drugs.
Discussion
NSCLC is extremely difficult to treat because of its low
therapeutic and long-term survival rates [11]. This study
demonstrates that a combination of COP or its major con-
stituent BER with chemotherapeutic drugs including
5-FU, CPT, and TAX exhibits a stronger inhibitory effect
on the growth of A549 human lung cancer cells than any
individual treatment. These findings suggest a potential
use of COP and BER in the adjuvant treatment of NSCLC.
ROS levels are elevated in cells exposed to various stres-
sors, including anticancer drugs, leading to apoptosis by
stimulating pro-apoptotic signaling molecules (e.g., P53,
MAPK, etc.) [25]. Some studies [13,22] have shown that
increasing the production of ROS may sensitize cancer
cells to drugs. Our results show that both COP and BER
Figure 3 Effects of COP and BER on ROS production in A549 cells. Cells were treated with COP-L (1.6 μg/mL), COP-H (6.4 μg/mL), BER-L
(0.5 μg/mL), or BER-H (4 μg/mL) for 24 h and harvested for ROS determination. * P<0.05 compared to control. Values are means±SD of 4
independent assays.
Figure 2 Growth inhibition by combined use of COP/BER and chemotherapeutic agents in A549 cells. Effects of COP or BER, combined
with 5-fluorouracil (5-FU), camptothecin (CPT), or paclitaxel (TAX), on the growth of A549 cells. COP-L: 1.6 μg/mL; COP-H: 6.4 μg/mL; BER-L:
0.5 μg/mL; BER-H: 4 μg/mL. *P<0.05, compared to drugs alone. Values are means±SD of 4 independent assays.
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dose-dependent manner, which is consistent with the
enhanced inhibitory effect of chemotherapeutic drugs
combined with COP or BER on A549 cancer cells.
Multiple drug resistance (MDR) is still the major cause
of cancer therapy failure. MDR involves the overexpres-
sion of membrane P-glycoprotein (Pgp) and a reduced
ability to accumulate and retain therapeutic drugs because
of the energy-dependent Pgp efflux pump. Almost all
NSCLC display intrinsic MDR, generally limiting the
chance of successful chemotherapy [23, 24]; this is a key
reason why lung cancer is currently a leading cause of
cancer death worldwide. Combined therapy with cytotoxic
drugs and MDR modulators is a promising strategy for
overcoming clinical MDR. Some traditional herbal medi-
cines, such as Coptis, Poria, and Zizyphi fructushave been
reported to reverse MDR [25]. Our results show that COP
and BER at low and high doses significantly increase the
retention of Rhodamine 123 dye, suggesting an inhibition
of P-gp and/or MRP efflux activity in the A549 cancer
cells. In turn, decreased MDR activity may contribute to
the inhibitory effects of chemotherapeutic drugs in con-
junction with COP and BER on A549 cancer cells. How-
ever, Lin et al. reported [26] that berberine up-regulated
MDR transporter pgp-170 expression and reduced the
response to paclitaxel in digestive track cancer cells. We
assume that different types of cell lines may respond dif-
ferently to berberine at certain concentrations.
The anticancer effects of COP and BER may involve
other pathways. Both 5-FU and CPT inhibit cellular DNA
replication [26,27], and TAX inhibits cell division by sta-
bilizing microtubules, triggering death of rapidly dividing
cancerous cells [28]. Some studies [29,30] have indicated
that COP and BER exhibit anticancer effects by inhibiting
the activity of DNA topoisomerases and protein kinase C.
Our previous study [9] showed that COP and BER
markedly inhibit cell proliferation and induce apoptotic
cell death of MCF-7 cells through up-regulation of inter-
feron-β, an important cytokine that regulates cell growth
and death. COP and BER also enhance the anticancer ef-
fect of estrogen receptor antagonists, including tamoxifen
and fulvestrant, likely by regulating multiple cancer-
related genes, e.g., EGFR, HER2, bcl-2, COX-2,a n dp21
[10]. In this study, we observed some differences in effi-
cacy between COP and BER. It may be that there were
components in COP other than BER that contributed to
its anticancer effect in agreement with our previous stud-
ies [9,10]. Further studies are required to discover the
pathways targeted by COP and BER.
Conclusions
This study demonstrated that combinations of COP or
BER with chemotherapeutic drugs (5-FU, CPT, and TAX)
are more effective in inhibiting the growth of A549 cells
than that of any single-agent therapy, possibly due to
increased production of ROS and reduce MDR.
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